After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's sales ...
As we previously reported, the U.S. Department of Justice (“DOJ”) filed a lawsuit under the Anti-Kickback Statute against Regeneron Pharmaceuticals in the District of Massachusetts regarding Regeneron ...
The U.S. Department of Justice on Wednesday accused Regeneron of defrauding Medicare by knowingly inflating the average sales price for its top-selling eye drug Eylea. In a lawsuit filed in U.S.
BOSTON, April 10 (Reuters) - The U.S. Justice Department on Wednesday accused Regeneron Pharmaceuticals (REGN.O), opens new tab of manipulating Medicare's drug-pricing process by inflating the average ...
Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results